Ralf Ludwig: When a Promising Biomarker Falls Short
Ralf Ludwig, Director of the Lübeck Institute of Experimental Dermatology at the University of Lübeck, shared a post on LinkedIn about a recent article by Ahmad Alsaber et al., published in Frontiers in Medicine, adding:
“A paper that went looking for a biomarker, found nothing, and got published on the strength of how well it looked.
That’s how it should work.
The third paper in our Research Topic is a null result – and it earns its place precisely because it is one.
The hypothesis was reasonable: in rheumatoid arthritis, inflammation reshapes lipid metabolism, so perhaps the triglyceride-to-HDL ratio could serve as a cheap surrogate for disease activity.
Tidy idea.
Using 1,212 adults from the Kuwait Registry for Rheumatic Diseases – a Gulf population where this question is barely studied – the authors tested it properly.
It didn’t hold.
TG/HDL showed no independent association with disease activity (DAS28).
Nor did LDL, HDL, or triglycerides alone.
The finding survived every stress test the authors threw at it: a higher activity threshold, continuous scoring, expanded confounder adjustment, subgroups by sex and obesity.
Reliably, robustly null.
Which is the point.
A convenient surrogate that doesn’t work is worth knowing before someone builds a clinic pathway on it – and the authors are admirably plain about their own limitations.
Negative findings from under-represented populations are exactly the kind of honest science that tends to die in a file drawer.
This one didn’t.
Paper 3 of seven now published in the collection.
Congratulations to Ahmad Alsaber and colleagues …!
Submit your study․”
Title: Lipid parameters and disease activity in rheumatoid arthritis: a cross-sectional analysis of the Kuwait registry for rheumatic diseases (KRRD)
Authors: Fatima Ali, Ghaydaa Aldabie, Ahmad Alsaber
Stay updated with Hemostasis Today.
-
Oct 12, 2026, 17:15Cedric Hermans: Identifying and Diagnosing Hemophilia Carriers and Affected Females
-
Oct 12, 2026, 17:01Bianca Rocca: Evaluating Factor XI Inhibition Lessons from LIBREXIA-ACS
-
Oct 12, 2026, 13:58Francisco Chacón-Lozsán: Catastrophic Antiphospholipid Syndrome A Rapidly Progressive Multiorgan Thrombotic Emergency
-
Oct 12, 2026, 12:50Nawsherwan Mohammad: Study Examines Thrombotic Events in Patients with Polycythemia Vera in Iraq
-
Oct 12, 2026, 12:30Chanakya Nayudu: Looking Beyond Blood Clots – Patient-Reported Outcomes in Antiphospholipid Syndrome
-
Oct 12, 2026, 12:12Jean-Jacques Kiladjian: Improving Treatment Strategies with JAK Inhibitors in Myelofibrosis
-
Oct 12, 2026, 12:04Chloe Homich: AABB Annual Meetings – Building Connections and Advancing Transfusion Medicine
-
Oct 12, 2026, 11:51Daniel Sop: Sickle Cell Research Takes Center Stage at ASCAT 2026
-
Oct 12, 2026, 10:36PAI-1 Inhibition as a New Strategy for Enhancing Fibrinolysis and Clot Resolution